Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 8.7% Higher – Time to Buy?

03 Apr 2026, 11:32 by Tristan Rich · The Markets Daily

Shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Get Free Report) were up 8.7% during mid-day trading on Wednesday . The stock traded as high as $1.6750 and last traded at $1.6960. Approximately 700,547 shares were traded during trading, a decline of 76% from the average daily volume of 2,868,474 shares. The stock had previously closed at $1.56.

Analysts Set New Price Targets

LXRX has been the topic of a number of research analyst reports. Citigroup raised their price objective on shares of Lexicon Pharmaceuticals from $2.10 to $2.30 and gave the stock a “buy” rating in a report on Tuesday, March 10th. HC Wainwright reaffirmed a “buy” rating and issued a $6.00 target price on shares of Lexicon Pharmaceuticals in a research note on Monday, March 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and an average target price of $4.15.

Check Out Our Latest Analysis on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Stock Down 3.0%

The company has a market capitalization of $673.65 million, a P/E ratio of -11.36 and a beta of 0.94. The firm’s 50 day moving average price is $1.51 and its two-hundred day moving average price is $1.40. The company has a current ratio of 4.88, a quick ratio of 4.87 and a debt-to-equity ratio of 0.46.

Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last announced its quarterly earnings data on Thursday, March 5th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 101.08% and a negative return on equity of 41.94%. The business had revenue of $5.49 million for the quarter, compared to analyst estimates of $3.14 million. Equities research analysts forecast that Lexicon Pharmaceuticals, Inc. will post -0.66 EPS for the current year.

Insider Activity

In related news, Director Raymond Debbane bought 100,000 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were acquired at an average price of $1.47 per share, with a total value of $147,000.00. Following the completion of the transaction, the director owned 1,904,186 shares in the company, valued at $2,799,153.42. The trade was a 5.54% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Invus Global Management, Llc bought 1,538,462 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The shares were bought at an average price of $1.30 per share, for a total transaction of $2,000,000.60. Following the acquisition, the director directly owned 1,538,462 shares of the company’s stock, valued at $2,000,000.60. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired a total of 1,790,462 shares of company stock worth $2,369,981 over the last three months. Insiders own 14.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Security National Bank of Sioux City Iowa IA acquired a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at approximately $31,000. Hudson Bay Capital Management LP bought a new stake in Lexicon Pharmaceuticals during the second quarter worth $26,000. Leonteq Securities AG acquired a new stake in Lexicon Pharmaceuticals in the fourth quarter valued at $34,000. Vermillion & White Wealth Management Group LLC lifted its stake in Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 26,000 shares during the last quarter. Finally, EntryPoint Capital LLC acquired a new position in shares of Lexicon Pharmaceuticals during the 4th quarter worth about $39,000. Institutional investors and hedge funds own 74.70% of the company’s stock.

Lexicon Pharmaceuticals Company Profile

(Get Free Report)

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.